Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFβ1 in melanoma enhances tumor infiltration and immunosuppression

Cancer Research

Volumn 71, Issue 3, 2011, Pages 812-821

  Díaz Valdés, Nancy ^a   Basagoiti, María ^a   Dotor, Javier ^b   Aranda, Fernando ^a   Monreal, Iñaki ^a   Riezu Boj, José Ignacio ^a   Borrás Cuesta, Francisco ^a   Sarobe, Pablo ^a   Feijoó, Esperanza ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Digna Biotech   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; B RAF KINASE; BASIC FIBROBLAST GROWTH FACTOR; CD40 ANTIBODY; DISITERTIDE; INTERLEUKIN 10; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; OVALBUMIN; PHOSPHATIDYLINOSITOL 3 KINASE; POLYINOSINIC POLYCYTIDYLIC ACID; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADJUVANT THERAPY; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER REGRESSION; CELL ACTIVATION; CELL INFILTRATION; CELL MIGRATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MELANOMA B16; MELANOMA CELL; MOLECULAR INTERACTION; MONOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SUPERNATANT; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; CHEMOKINE CCL2; FEMALE; HUMANS; INTERLEUKIN-10; MAP KINASE SIGNALING SYSTEM; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, NUDE; MOLECULAR SEQUENCE DATA; MONOCYTES; PROTO-ONCOGENE PROTEINS C-AKT; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79551532830     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2698     Document Type: Article

References (44)

1. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-29.
2. Javelaud D, Alexaki VI, Mauviel A. Transforming growth factor-beta in cutaneous melanoma. Pigment Cell Melanoma Res 2008;21:123-32.
3. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998;16:137-61.
4. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest 1993;92:2569-76.
5. Wrzesinski SH, Wan YY, Flavell RA. Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res 2007;13:5262-70.
6. Moretti S, Pinzi C, Berti E, Spallanzani A, Chiarugi A, Boddi V, et al. In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res 1997;7:313-21.
7. Shi Y, Hata A, Lo RS, Massague J, Pavletich NP. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 1997;388:87-93.
8. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2003;3:807-21. (Pubitemid 37376979)
9. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med 2008;359:2814-23.
10. Lopez-Bergami P, Ronai Z. Requirements for PKC-augmented JNK activation by MKK4/7. Int J Biochem Cell Biol 2008;40:1055-64.
11. Lazar-Molnar E, Hegyesi H, Toth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000;12:547-54.
12. Nesbit M, Schaider H, Miller TH, Herlyn M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol. 2001;166:6483-90.
13. Dirkx AE, Oude Egbrink MG, Wagstaff J, Griffioen AW. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol 2006;80:1183-96.
14. Chen Q, Daniel V, Maher DW, Hersey P. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 1994;56:755-60.
15. Moretti S, Chiarugi A, Semplici F, Salvi A, De Giorgi V, Fabbri P, et al. Serum imbalance of cytokines in melanoma patients. Melanoma Res. 2001;11:395-9.
16. Nemunaitis J, Fong T, Shabe P, Martineau D, Ando D. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest 2001;19:239-47.
17. Ezquerro IJ, Lasarte JJ, Dotor J, Castilla-Cortazar I, Bustos M, Penuelas I, et al. A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine 2003;22:12-20.
18. Echeverria I, Zabaleta A, Silva L, Diaz-Valdes N, Riezu-Boj JI, Lasarte JJ, et al. Monocyte-derived dendritic cells from HCV-infected patients transduced with an adenovirus expressing NS3 are functional when stimulated with the TLR3 ligand poly(I:C). J Viral Hepat 2008;15:782-9.
19. Larrea E, Riezu-Boj JI, Gil-Guerrero L, Casares N, Aldabe R, Sarobe P, et al. Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol 2007;81:3662-6.
20. Loughlin PM, Cooke TG, George WD, Gray AJ, Stott DI, Going JJ. Quantifying tumour-infiltrating lymphocyte subsets: a practical immuno-histochemical method. J Immunol Methods 2007;321:32-40.
21. + T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 2003;171:5931-9.
22. Ma J, Wang Q, Fei T, Han JD, Chen YG. MCP-1 mediates TGF-beta-induced angiogenesis by stimulating vascular smooth muscle cell migration. Blood 2007;109:987-94.
23. Zhang F, Tsai S, Kato K, Yamanouchi D, Wang C, Rafii S, et al. Transforming growth factor-beta promotes recruitment of bone marrow cells and bone marrow-derived mesenchymal stem cells through stimulation of MCP-1 production in vascular smooth muscle cells. J Biol Chem 2009;284:17564-74.
24. Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S, et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997;71:630-7. (Pubitemid 27239375)
25. Penafuerte C, Galipeau J. TGF beta secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect. Cancer Immunol Immunother 2008;57:1197-206.
26. Sredni B, Weil M, Khomenok G, Lebenthal I, Teitz S, Mardor Y, et al. Ammonium trichloro(dioxoethylene-O,O0)tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Res 2004;64:1843-52.
27. Ilkovitch D, Lopez DM. Immune modulation by melanoma-derived factors. Exp Dermatol 2008;17:977-85.
28. Gazzaniga S, Bravo AI, Guglielmotti A, van Rooijen N, Maschi F, Vecchi A, et al. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol 2007;127:2031-41.
29. Yue J, Mulder KM. Activation of the mitogen-activated protein kinase pathway by transforming growth factor-beta. Methods Mol Biol 2000;142:125-31.
30. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003;425:577-84.
31. Moustakas A, Heldin CH. Non-Smad TGF-beta signals. J Cell Sci 2005;118:3573-84.
32. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006;203:1651-6.
33. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
34. Graells J, Vinyals A, Figueras A, Llorens A, Moreno A, Marcoval J, et al. Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol 2004;123:1151-61.
35. DiSerio C, Doria L, Pellerito S, Prudovsky I, Micucci I, Massi D, et al. The release of fibroblast growth factor-1 from melanoma cells requires copper ions and is mediated by phosphatidylinositol 3-kinase/Akt intracellular signaling pathway. Cancer Lett 2008;267:67-74.
36. Mills CD. Macrophage arginine metabolism to ornithine/urea or nitric oxide/citrulline: a life or death issue. Crit Rev Immunol 2001;21:399-425.
37. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55.
38. Halaban R. Growth factors and tyrosine protein kinases in normal and malignant melanocytes. Cancer Metastasis Rev 1991;10:129-40.
39. Tao J, Tu YT, Li JW, Feng AP, Huan CZ, Wu Y, et al. Endogenous production of nitric oxide contributes to proliferation effect of vascular endothelial growth factor-induced malignant melanoma cell. Clin Exp Dermatol 2006;31:94-9.
40. Koga M, Kai H, Egami K, Murohara T, Ikeda A, Yasuoka S, et al. Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem Biophys Res Commun 2008;365:279-84.
41. Llopiz D, Dotor J, Casares N, Bezunartea J, Diaz-Valdes N, Ruiz M, et al. Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy. Int J Cancer 2009;125:2614-23.
42. Kim S, Buchlis G, Fridlender ZG, Sun J, Kapoor V, Cheng G, et al. Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res 2008;68:10247-56.
43. Nam JS, Terabe M, Mamura M, Kang MJ, Chae H, Stuelten C, et al. An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 2008;68:3835-43.
44. Ueda R, Fujita M, Zhu X, Sasaki K, Kastenhuber ER, Kohanbash G, et al. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res 2009;15:6551-9.